Src-1 expression is significantly upregulated in nearly 20% breast cancer, and is associated with positive HER2 expression, large and high grade tumor, disease recurrence, poor survival and resistance to endocrine therapy [15, 16]. Here, ERBB2 is linked to neoplasm.